Objectives: To determine trends in ciprofloxacin resistance and co-resistance to other antibiotic classes in blood isolates of Escherichia coli, and to investigate if there is an ecological relationship to the community use of fluoroquinolones and other antibiotics.
Introduction
Escherichia coli is one of the most prevalent microorganisms, and is known to cause both nosocomial and community-acquired infections. 1, 2 Resistance to several antimicrobial agents is not uncommon for this pathogen. 3 Fluoroquinolone resistance and extended-spectrum b-lactamase (ESBL) production in E. coli have increased worldwide in the last decade. 1 In many countries, fluoroquinolones are one of the most used antibiotics. 4 The European Antimicrobial Resistance Surveillance Network (EARS-Net) is focused on the surveillance of antimicrobial resistance in invasive pathogens. According to EARS-Net, the rate of fluoroquinolone resistance in blood isolates of E. coli varies among European countries (http://www.rivm.nl/earss). 4 While some studies have failed to identify a link or have identified a very weak association between fluoroquinolone resistance in E. coli and fluoroquinolone use, others have suggested that the variation in fluoroquinolone use is consistent with the occurrence of fluoroquinolone resistance at the country level. 5, 6 Robust conclusions between resistance and usage may be difficult to achieve, due to confounding factors such as clonal dissemination and lack of statistical power.
Spain has high rates of both antibiotic resistance and antibiotic use, and might be an acceptable setting for the investigation into whether or not the use of fluoroquinolones and other antibiotic families is influencing the rapid increase in fluoroquinolone resistance in E. coli. In this study, we hypothesized that, although the rapid evolution of fluoroquinolone resistance in E. coli is likely a multifaceted event, the burden of antibiotic use by the general population is a definitive factor from the ecological standpoint.
The aims of this study included: (i) determination of trends in ciprofloxacin resistance and co-resistance to other antibiotic classes in blood isolates of E. coli collected by Spanish hospitals of the EARS-Net over a 9 year period (2001 -09); (ii) analysing trends in the community use of fluoroquinolones and other antibiotics over a 12 year period (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) ; and (iii) investigating the ecological relationship between the progression of fluoroquinolone resistance in E. coli causing bacteraemia and the community use of antibiotics.
Materials and methods

Antibiotic resistance
Forty-two Spanish hospitals participating in the EARS-Net collected antibiotic susceptibility data for all first blood E. coli isolates from each patient from 2001 to 2009. Selection of these hospitals was performed according to EARS-Net criteria and selected hospitals were evenly distributed across the country. 1, 3 These hospitals serve 13 million people, which represents 30% of the total Spanish population.
Each laboratory identified strains and tested their susceptibilities according to standard microbiological procedures, by using commercial microdilution broth systems. 7 Results were scored as susceptible, intermediate or resistant, according to criteria established by the CLSI. 8 For ciprofloxacin-non-susceptible (CIPNS) strains, multidrug resistance was defined as resistance to an additional two or more of the following antibiotics: ampicillin; cefotaxime; gentamicin; and co-trimoxazole. A quality assurance exercise (UK National External Quality Assessment Scheme) was performed annually to ensure comparable results among the hospital laboratories.
Nosocomial infections were defined according to the EARS-Net definition as infections acquired ≥48 h after hospital admission. Patients with community-acquired infections were identified as those who had positive E. coli cultures at the time of or within 48 h of hospitalization. All susceptibility data were compiled and analysed with WHONET (http:// www.who.int/drugresistance/whonetsoftware/en/).
Antibiotic use
Data regarding the nationwide ambulatory use of antibiotics between 1997 and 2008 were provided by the Spanish Agency for Medicines and Medical Devices (Ministry of Health and Social Policy) and obtained from the Especialidades Consumo de Medicamentos database of retail pharmacy sales of all medicines acquired with National Health System prescriptions. This strategy covered nearly 100% of the Spanish population. The information was tabulated per year and the number of units was converted into defined daily doses (DDDs) of each antibiotic following WHO methodology. 9 We then expressed the number of DDDs per 1000 inhabitants per day (DIDs) for each of the active drug ingredients.
Statistical analysis
The significance of the antimicrobial resistance trends was calculated by the x 2 test. Trends in antibiotic use were examined by regression model analysis. Statistical analysis of predictors of infection was performed using univariate and multivariate analysis. Variables for which P values were ,0.1 in the univariate analysis were further examined in the multivariate model using logistic regression. The strength of the association between antibiotic use and ciprofloxacin resistance was determined by linear regression analysis. The proportion of resistance was transformed to the natural logarithm of the odds of resistance. The log odds of resistance (as the dependent variable) was expressed as a simple linear function of the independent variable (antibiotic use). 6 Ciprofloxacin resistance for 2001-09 was correlated with the antibiotic use in the year before. All differences for which P values were ,0.05 were considered statistically significant. Data were analysed using the SPSS 13.0 software package.
Results
Patients and isolates
The 42 participating hospitals reported data on 28 307 consecutive E. coli blood infections, corresponding to the same number of patients; 14352 patients (50.7%) were males and 27231 (96.2%) were adults (.14 years). The E. coli isolated from 16 361 (57.8%) patients caused community-acquired infections. The blood cultures were obtained from patients in the following locations: emergency room (39.2%); internal medicine (30.3%); surgery (6.9%); intensive care units (6.6%); paediatrics (2.1%); and other departments (14.9%). 
Ciprofloxacin resistance
Ciprofloxacin and other antibiotic resistance trends
The annual rates of CIPNS E. coli increased from 17.6% (2001) to 32.7% (2009) (x 2 for trend 315.1; P,0.0001). The percentage of CIPNS increased in all participating hospitals. This increase was observed in isolates causing both nosocomial infections (13.8% change; x 2 for trend 115.2; P,0.0001) and community-acquired infections (17.3% change; x 2 for trend 217; P,0.0001). CIPNS E. coli causing community-acquired infections increased faster than nosocomial isolates.
The proportion of CIPNS E. coli producing an ESBL or nonsusceptible to amoxicillin/clavulanic acid or tobramycin continually increased between 2003 and 2009 (Figure 1 
Predictors of infection with CIPNS
Males and adults over age 65 years had a higher risk of infection from CIPNS isolates ( Table 1) . By univariate analysis, patients admitted to the internal medicine service had a higher risk of infection with CIPNS E. coli, but this association was not confirmed by multivariate analysis ( Table 1 ). E. coli infections acquired after 48 h of admission were significantly associated with a higher risk of being identified as CIPNS. Also, E. coli producing ESBLs or non-susceptible to amoxicillin/ clavulanic acid or aminoglycosides (gentamicin and/or tobramycin) had a higher risk of being identified as CIPNS in all cases (Table 1) . 
Community antibiotic use
Correlation of CIPNS with community antibiotic use
Yearly rates of CIPNS E. coli showed a good correlation with outpatient use of fluoroquinolones (r 2 ¼0.68; P ¼0.006) or amoxicillin/clavulanic acid in the previous year, with the strongest correlations being observed for moxifloxacin, levofloxacin and amoxicillin/clavulanic acid (Figure 2) . CIPNS rates strongly correlated with the use of levofloxacin plus moxifloxacin (r 
Discussion
Although antibiotic resistance is a complex subject, the use and misuse of antibiotics are known to play pivotal roles in its development. 6 In addition to the use of fluoroquinolones, other factors, including clonal dissemination or transmission by the Figure 1 . Relationships between ciprofloxacin susceptibility in blood isolates of E. coli and evolution of ESBL production (a), amoxicillin/ clavulanic acid non-susceptibility (b) and tobramycin non-susceptibility (c).
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ingestion of contaminated food from animals, can be implicated in the spread of ciprofloxacin resistance in E. coli. In Europe, ecological studies based on routine surveillance data have shown a relationship between antibiotic use and resistance, and promote interventions to reduce antimicrobial use at a national level. 6 Although community use of antibiotics constitutes 90% of the total human use, 4 a limitation of this study was that national representative data of hospital and veterinary use were not available.
In urinary pathogens, prolonged use of low doses of fluoroquinolones, such as ciprofloxacin or levofloxacin, was identified as a significant risk factor for the acquisition of fluoroquinolone 12 A multicentre study from Finland failed to demonstrate an association between fluoroquinolone use and fluoroquinolone resistance in E. coli. 5 It has been suggested that co-selection of resistance can be the consequence of the use of different antimicrobial families. 13 In a recent study performed in France, the authors suggest that ciprofloxacin resistance in E. coli in hospital is linked to the consumption of fluoroquinolones within the hospital and its surrounding community, and, among all fluoroquinolones, levofloxacin use was found to be the most important factor. 14 In this study, we report a number of findings of potential epidemiological, clinical and public health interest, including: (i) CIPNS E. coli causing bacteraemia constitute an extraordinary and rapidly progressing problem at both the community and nosocomial level; (ii) the rapid progress of CIPNS E. coli is closely related to the progression of resistance to amoxicillin/ clavulanic acid and aminoglycosides, and the production of ESBLs; (iii) for the first time, we have shown that increased amoxicillin/clavulanic acid use (the most used antibiotic in Spain and other countries) correlates with an increased resistance to ciprofloxacin in blood isolates of E. coli-this finding is probably due to a co-selection event; 13 (iv) increased community use of fluoroquinolones (mainly moxifloxacin and levofloxacin) and amoxicillin/clavulanic acid correlates with ciprofloxacin resistance in E. coli; and (iv) current and future actions addressed at the improvement of fluoroquinolone resistance in E. coli should be focused on the prudent use of antibiotics, paying special attention to the use of moxifloxacin and levofloxacin, as well as other antibiotic families.
